Dr. Reddy’s Laboratories Ltd (RDY) has released an update.
Dr. Reddy’s Laboratories Ltd. has initiated a voluntary nationwide recall of six lots of Sapropterin Dihydrochloride Powder due to discoloration and sub-potency, which could lead to serious health risks, including intellectual disability and developmental delay in children. Although no adverse events have been reported, the medication, used to treat elevated blood phenylalanine levels in patients with Phenylketonuria, is being withdrawn from the market and the company is coordinating product returns. Consumers in possession of the affected product are advised to consult their healthcare provider and return the medication to their place of purchase.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.
